# Debora Dumont

> Debora Dumont is a seed investor at Enhanc3D Genomics backing Biotechnology and Therapeutics. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Enhanc3D Genomics](https://shizune.co/investors/profile/enhanc3d-genomics)
- Total investments: 4
- Last investment: Jun 2025
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/debora-dumont/2/443/738

Debora Dumont is a seed investor at Enhanc3D Genomics focused on Biotechnology and Therapeutics. Debora Dumont is the Managing Partner & Co-founder at Bioqube Ventures. He attended Hasselt University in 2002.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 75% |
| Therapeutics | 2 | 50% |
| Life Science | 1 | 25% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 50% |
| Series A | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Belgium | 1 | 25% |
| United States | 1 | 25% |
| The Netherlands | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Spica Therapeutics | Spica Therapeutics is a biotech company to transform macrophage biology into breakthrough therapies for patients. | $11.4M | Seed | Jun 04, 2025 |  |
| Anavo Therapeutics | Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades. We have attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. In oncology, Anavois developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications | $9.4M | Seed | May 02, 2023 |  |
| Enhanc3D Genomics | Enhanc3D Genomics is a spinout company from Babraham Institute. | $11.2M | Series A | Oct 20, 2022 |  |
| Anavo Therapeutics | Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades. We have attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. In oncology, Anavois developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications | $24M | Seed | Apr 22, 2021 |  |

4 of 4 investments shown.

## Co-investors
- [Inkef](https://shizune.co/investors/profile/inkef-capital) — VC Fund, 2 deals together
- [M Ventures](https://shizune.co/investors/profile/merckventures) — VC Fund, 2 deals together
- [Taiho Ventures](https://shizune.co/investors/profile/taiho-ventures-2) — VC Fund, 2 deals together
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund, 1 deal together
- [MRL Ventures Fund](https://shizune.co/investors/profile/mrl-venture-fund) — VC Fund, 1 deal together
- [Parkwalk Advisors](https://shizune.co/investors/profile/parkwalk-advisors) — VC Fund, 1 deal together

## About Enhanc3D Genomics

VC Fund · Cambridge, United States

Enhanc3D Genomics is a spinout company from Babraham Institute.

1 contacts available at Enhanc3D Genomics.

| Name | Title | Profile |
| --- | --- | --- |
| Debora Dumont | Director | https://shizune.co/investors/profile/debora-dumont |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Debora Dumont invest in?

Debora Dumont invests primarily in Biotechnology, Therapeutics and Life Science startups, most often at Seed and Series A stage. Most of the 4 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Debora Dumont last invest?

The most recent investment recorded for Debora Dumont closed in Jun 2025. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co